Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Evaluation of the efficacy and safety of Ganovo combined with ritonavir for patients infected with SARS-CoV-2.
Description: Defined as SPO2≤ 93% without oxygen supplementation, PaO2/FiO2 ≤300mmHg or a respiratory rate ≥30 breaths per min without supplemental oxygen
Measure: Rate of composite adverse outcomes Time: 14 daysDescription: Clinical recovery was defined as sustained (48 hours) alleviation of illness based on symptom scores (fever, cough, diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline ≥3%, respiratory rate ≥ 24 breaths per min without supplemental oxygen).
Measure: Time to recovery Time: 14 daysDescription: Rate of no fever
Measure: Rate of no fever Time: 14 daysDescription: Rate of no cough
Measure: Rate of no cough Time: 14 daysDescription: Rate of no dyspnea
Measure: Rate of no dyspnea Time: 14 daysDescription: Rate of no requiring supplemental oxygen
Measure: Rate of no requiring supplemental oxygen Time: 14 daysDescription: Rate of undetectable New coronavirus pathogen nucleic acid
Measure: Rate of undetectable New coronavirus pathogen nucleic acid Time: 14 daysDescription: Rate of mechanical ventilation
Measure: Rate of mechanical ventilation Time: 14 daysDescription: Rate of ICU admission
Measure: Rate of ICU admission Time: 14 daysDescription: Rate of serious adverse event
Measure: Rate of serious adverse event Time: 14 days